Pharmaceutical

TNF and Renova Health use AI to identify patients for GLP-1 treatments

TNF and Renova Health are set to use AI and ML for the identification of high-risk subjects who could benefit from GLP-1 therapies

Apr 24, 2025 - 06:00
TNF and Renova Health use AI to identify patients for GLP-1 treatments
TNF and Renova Health are set to use AI and ML for the identification of high-risk subjects who could benefit from GLP-1 therapies
Read the original article

Tags:

Previous Article

ConcertAI and Bayer to boost precision oncology with AI and ML insights

Next Article

First two medicinal products to undergo EU joint clinical assessments announced

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Obesity market expected to reach $37.1bn across 7MM by 2031

Obesity market expected to reach $37.1bn across 7MM by ...

Mar 29, 2023

Bayer’s stock drops to new 18-year low after asundexian trial termination

Bayer’s stock drops to new 18-year low after asundexian...

Nov 28, 2023

FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy

FDA RMAT status for Affimed and Artiva’s lymphoma combo...

Dec 9, 2024